

CONTACT: Brian Bennett
(501)225-9733



(For Immediate Release)

STUDY SHOWS INVESTIGATOR RATINGS PREDICT A TRIAL'S SUCCESS
i3 Pharma Informatics Launches Clinical Informatics Solutions Group

BASKING RIDGE, NJ, April 20, 2009—A new retrospective study of 232 clinical trial investigators shows that i3's ratings enhance the ability to predict success in patient enrollment and retention. The i3 system uses de-identified insurance claims to calculate the percentage of each investigator's patients who qualify for a trial. Success is predicted when an investigator has a high percentage of patients who match the trial's criteria. The study was conducted by the new Clinical Informatics team housed within i3 Pharma Informatics.

Clinical Informatics Solutions uses one of the nation's largest private databases of insurance claims to create solutions to improve the speed and likelihood of success of trials. This study leveraged its feasibility analysis service which, combined with related capabilities, is used to rank all physicians who might be investigators, rank geographies for patient availability, and determine trial feasibility based on national patient counts. The site selection capability pinpoints both the investigators with the most patients, as well as those geographies with the highest concentrations of appropriate patients for more successful trials.

The study showed the top 30 percent of investigators—physicians who are high enrollers—recruit 70 percent of the trial's total patients.

“Our capabilities find the high enrollers, increasing the trial's speed,” said Bill Gwinn, vice president of Clinical Informatics. “Industry data show that 70 percent of American trials run late. Our feasibility analysis service helps identify unrealistic protocol criteria and helps our sponsors plan more sites when patient counts are low.”

Gwinn joins i3 as an expert in quantitative analysis for selecting the best clinical trial sites and finding new patients. His past experience includes positions at Inclinix and The Medstat Group at Thomson Reuters.

About i3

i3, a global Ingenix company, provides integrated scientific strategies and solutions throughout the pharmaceutical product lifecycle. It is composed of i3 Research, a therapeutically specialized contract research organization; i3 Drug Safety, engaged in pharmacovigilance and epidemiology; i3 Pharma Informatics, a data, science and technology provider of market analytics; i3 Statprobe, a leader in comprehensive data services; i3 Pharma Resourcing, a world-class staffing partner; and i3 Innovus, delivering the science and solutions to achieve marketplace success. i3 helps companies gain sharper insights that lead to better patient care. For more information, visit www.i3global.com.

#